Latest news with #TheRoyalMarsden
Wales Online
18-06-2025
- Health
- Wales Online
Princess Kate pulls out of Royal Ascot 'at the last minute'
Princess Kate pulls out of Royal Ascot 'at the last minute' The 43-year-old royal was expected to join her husband, Prince William, King Charles and Queen Camilla in the traditional carriage procession at the Berkshire racecourse The Princess of Wales has reportedly said she will not be in attendance for Ascot today (Image: Chris Jackson/PA Wire ) Catherine, Princess of Wales pulled out of attending Royal Ascot "at the last minute" on Wednesday (18.06.25). The 43-year-old royal was expected to join her husband, Prince William, King Charles and Queen Camilla in the traditional carriage procession at the Berkshire racecourse. However, she is believed to have cancelled the engagement as she tries to "find the right balance" amid her gradual return to royal duties, following her battle with cancer. Royal correspondent Chris Ship shared to X: "Prince William will be at @Ascot today as expected but the Princess of Wales has decided, at the last minute, not to attend today. Ascot had previously named her in the second carriage. "It's understood she's decided to find the right balance as she returns to public engagements." Catherine was present at the Trooping the Colour event at Horse Guards Parade in London on Saturday (14.06.25). Article continues below The princess underwent abdominal surgery in January 2024 and later revealed she was undergoing preventative chemotherapy, before confirming in January this year that she was in remission. Catherine - who has Prince George, 11, Princess Charlotte, 10, and Prince Louis, seven, with the future king - revealed she was cancer-free as she paid tribute to the staff at the Royal Marsden Hospital in west London, where she received treatment. She wrote on her and William's social media channels: "I wanted to take the opportunity to say thank you to The Royal Marsden for looking after me so well during the past year. "My heartfelt thanks goes to all those who have quietly walked alongside William and me as we have navigated everything. "We couldn't have asked for more. The care and advice we have received throughout my time as a patient has been exceptional. "In my new role as Joint Patron of The Royal Marsden, my hope is, that by supporting groundbreaking research and clinical excellence, as well as promoting patient and family wellbeing, we might save many more lives, and transform the experience of all those impacted by cancer. "It is a relief to now be in remission and I remain focussed on recovery. As anyone who has experienced a cancer diagnosis will know, it takes time to adjust to a new normal. I am however looking forward to a fulfilling year ahead. There is much to look forward to. Thank you to everyone for your continued support. C (sic)" The princess went public with her cancer diagnosis in March 2024, and praised her husband for his support. She said at the time: "It has taken me time to recover from major surgery in order to start my treatment. But, most importantly, it has taken us time to explain everything to George, Charlotte and Louis in a way that is appropriate for them, and to reassure them that I am going to be OK. Article continues below "As I have said to them; I am well and getting stronger every day by focusing on the things that will help me heal; in my mind, body and spirits. "Having William by my side is a great source of comfort and reassurance too. As is the love, support and kindness that has been shown by so many of you. It means so much to us both."
Perth Now
18-06-2025
- Health
- Perth Now
Princess Catherine pulls out of Royal Ascot 'at the last minute'
Catherine, Princess of Wales pulled out of attending Royal Ascot "at the last minute" on Wednesday (18.06.25). The 43-year-old royal was expected to join her husband, Prince William, King Charles and Queen Camilla in the traditional carriage procession at the Berkshire racecourse. However, she is believed to have cancelled the engagement as she tries to "find the right balance" amid her gradual return to royal duties, following her battle with cancer. Royal correspondent Chris Ship shared to X: "Prince William will be at @Ascot today as expected but the Princess of Wales has decided, at the last minute, not to attend today. Ascot had previously named her in the second carriage. "It's understood she's decided to find the right balance as she returns to public engagements." Catherine was present at the Trooping the Colour event at Horse Guards Parade in London on Saturday (14.06.25). The princess underwent abdominal surgery in January 2024 and later revealed she was undergoing preventative chemotherapy, before confirming in January this year that she was in remission. Catherine - who has Prince George, 11, Princess Charlotte, 10, and Prince Louis, seven, with the future king - revealed she was cancer-free as she paid tribute to the staff at the Royal Marsden Hospital in west London, where she received treatment. She wrote on her and William's social media channels: "I wanted to take the opportunity to say thank you to The Royal Marsden for looking after me so well during the past year. "My heartfelt thanks goes to all those who have quietly walked alongside William and me as we have navigated everything. "We couldn't have asked for more. The care and advice we have received throughout my time as a patient has been exceptional. "In my new role as Joint Patron of The Royal Marsden, my hope is, that by supporting groundbreaking research and clinical excellence, as well as promoting patient and family wellbeing, we might save many more lives, and transform the experience of all those impacted by cancer. "It is a relief to now be in remission and I remain focussed on recovery. As anyone who has experienced a cancer diagnosis will know, it takes time to adjust to a new normal. I am however looking forward to a fulfilling year ahead. There is much to look forward to. Thank you to everyone for your continued support. C (sic)" The princess went public with her cancer diagnosis in March 2024, and praised her husband for his support. She said at the time: "It has taken me time to recover from major surgery in order to start my treatment. But, most importantly, it has taken us time to explain everything to George, Charlotte and Louis in a way that is appropriate for them, and to reassure them that I am going to be OK. "As I have said to them; I am well and getting stronger every day by focusing on the things that will help me heal; in my mind, body and spirits. "Having William by my side is a great source of comfort and reassurance too. As is the love, support and kindness that has been shown by so many of you. It means so much to us both."
North Wales Chronicle
02-06-2025
- Health
- North Wales Chronicle
One-time therapy may be ‘transformative option' for treating deadly skin cancer
Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking in the majority of cases, a trial has found. Lifileucel is a tumour-infiltrating lymphocyte (TIL) therapy, which involves isolating T cells – a type of white blood cell – from tumours and growing them in a lab before infusing them back into the patient where they can recognise and fight cancer. It could become a 'transformative option' for patients with this type of skin cancer, experts said. Cancer Research UK estimates that there are about 20,800 new cases of melanoma diagnosed in the UK every year. Advanced melanoma, also known as stage four melanoma, means the disease has spread to other parts of the body. The C-144-01 trial involved 153 patients from Europe and the US, and was led by The Royal Marsden NHS Foundation Trust. At a five-year follow up, 19.7% of patients were still alive with no new or delayed side effects. The trial also found that tumours shrank in almost four out of five (79.3%) patients, while one in 20 (5.9%) showed no evidence of cancer. Dr Andrew Furness, a consultant medical oncologist who led the trial at The Royal Marsden NHS Foundation Trust, said: 'While current forms of immunotherapy have revolutionised the treatment of cancer in recent years, overall these benefit a minority rather than majority of treated patients. 'Results from this trial have shown that TIL therapy may change the outlook for people with advanced melanoma.' Lifileucel is not yet approved for use in the UK, but was given the green light by the US Food and Drug Administration (FDA) for the treatment of advanced melanoma in February 2024. Trials are also looking at using the TIL therapy in combination with pembrolizumab, sold under the brand name Keytruda, for people with advanced melanoma. Keytruda works by targeting and blocking a protein known as PD-L1, which is found on T cells, to help the immune system fight cancer more effectively. Dr Furness added: 'We're continuing our research into the use of TIL therapy, as well as other forms of cellular therapy, across a broader spectrum of cancers including advanced lung, liver, ovary, skin and testicular subtypes as well as soft tissue sarcoma.' Study co-author James Larkin, consultant medical oncologist at The Royal Marsden and professor of precision cancer therapeutics at The Institute of Cancer Research, London, said: 'These significant results offer a compelling case for TIL therapy as a transformative option in melanoma care. 'The study demonstrates that for patients with few options left, a single infusion of lifileucel can provide a deep and lasting response and even complete remission in some cases. This marks a major advance in how we think about treating solid tumours.' Zoe Phillips, 46, from Dorset took part in the TIL therapy trial at The Royal Marsden. She was diagnosed with stage four melanoma in 2023 after previously being treated for skin cancer two years earlier. 'Six weeks after my first TIL therapy treatment, my scans showed that the tumours had completely disappeared,' Ms Phillips said. 'Before coming to The Royal Marsden I was told that I would probably die, so hearing that my treatment had been successful was amazing, I was over the moon. 'I come back to the hospital regularly for pembrolizumab immunotherapy treatment and currently still have no evidence of cancer.' Findings from the C-144-01 trial have been presented at the American Society of Clinical Oncology (Asco) annual meeting in Chicago.
South Wales Guardian
02-06-2025
- Health
- South Wales Guardian
One-time therapy may be ‘transformative option' for treating deadly skin cancer
Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking in the majority of cases, a trial has found. Lifileucel is a tumour-infiltrating lymphocyte (TIL) therapy, which involves isolating T cells – a type of white blood cell – from tumours and growing them in a lab before infusing them back into the patient where they can recognise and fight cancer. It could become a 'transformative option' for patients with this type of skin cancer, experts said. Cancer Research UK estimates that there are about 20,800 new cases of melanoma diagnosed in the UK every year. Advanced melanoma, also known as stage four melanoma, means the disease has spread to other parts of the body. The C-144-01 trial involved 153 patients from Europe and the US, and was led by The Royal Marsden NHS Foundation Trust. At a five-year follow up, 19.7% of patients were still alive with no new or delayed side effects. The trial also found that tumours shrank in almost four out of five (79.3%) patients, while one in 20 (5.9%) showed no evidence of cancer. Dr Andrew Furness, a consultant medical oncologist who led the trial at The Royal Marsden NHS Foundation Trust, said: 'While current forms of immunotherapy have revolutionised the treatment of cancer in recent years, overall these benefit a minority rather than majority of treated patients. 'Results from this trial have shown that TIL therapy may change the outlook for people with advanced melanoma.' Lifileucel is not yet approved for use in the UK, but was given the green light by the US Food and Drug Administration (FDA) for the treatment of advanced melanoma in February 2024. Trials are also looking at using the TIL therapy in combination with pembrolizumab, sold under the brand name Keytruda, for people with advanced melanoma. Keytruda works by targeting and blocking a protein known as PD-L1, which is found on T cells, to help the immune system fight cancer more effectively. Dr Furness added: 'We're continuing our research into the use of TIL therapy, as well as other forms of cellular therapy, across a broader spectrum of cancers including advanced lung, liver, ovary, skin and testicular subtypes as well as soft tissue sarcoma.' Study co-author James Larkin, consultant medical oncologist at The Royal Marsden and professor of precision cancer therapeutics at The Institute of Cancer Research, London, said: 'These significant results offer a compelling case for TIL therapy as a transformative option in melanoma care. 'The study demonstrates that for patients with few options left, a single infusion of lifileucel can provide a deep and lasting response and even complete remission in some cases. This marks a major advance in how we think about treating solid tumours.' Zoe Phillips, 46, from Dorset took part in the TIL therapy trial at The Royal Marsden. She was diagnosed with stage four melanoma in 2023 after previously being treated for skin cancer two years earlier. 'Six weeks after my first TIL therapy treatment, my scans showed that the tumours had completely disappeared,' Ms Phillips said. 'Before coming to The Royal Marsden I was told that I would probably die, so hearing that my treatment had been successful was amazing, I was over the moon. 'I come back to the hospital regularly for pembrolizumab immunotherapy treatment and currently still have no evidence of cancer.' Findings from the C-144-01 trial have been presented at the American Society of Clinical Oncology (Asco) annual meeting in Chicago.
South Wales Argus
02-06-2025
- Health
- South Wales Argus
One-time therapy may be ‘transformative option' for treating deadly skin cancer
Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking in the majority of cases, a trial has found. Lifileucel is a tumour-infiltrating lymphocyte (TIL) therapy, which involves isolating T cells – a type of white blood cell – from tumours and growing them in a lab before infusing them back into the patient where they can recognise and fight cancer. It could become a 'transformative option' for patients with this type of skin cancer, experts said. Cancer Research UK estimates that there are about 20,800 new cases of melanoma diagnosed in the UK every year. Advanced melanoma, also known as stage four melanoma, means the disease has spread to other parts of the body. The C-144-01 trial involved 153 patients from Europe and the US, and was led by The Royal Marsden NHS Foundation Trust. At a five-year follow up, 19.7% of patients were still alive with no new or delayed side effects. The trial also found that tumours shrank in almost four out of five (79.3%) patients, while one in 20 (5.9%) showed no evidence of cancer. Dr Andrew Furness, a consultant medical oncologist who led the trial at The Royal Marsden NHS Foundation Trust, said: 'While current forms of immunotherapy have revolutionised the treatment of cancer in recent years, overall these benefit a minority rather than majority of treated patients. 'Results from this trial have shown that TIL therapy may change the outlook for people with advanced melanoma.' Lifileucel is not yet approved for use in the UK, but was given the green light by the US Food and Drug Administration (FDA) for the treatment of advanced melanoma in February 2024. Trials are also looking at using the TIL therapy in combination with pembrolizumab, sold under the brand name Keytruda, for people with advanced melanoma. Keytruda works by targeting and blocking a protein known as PD-L1, which is found on T cells, to help the immune system fight cancer more effectively. Dr Furness added: 'We're continuing our research into the use of TIL therapy, as well as other forms of cellular therapy, across a broader spectrum of cancers including advanced lung, liver, ovary, skin and testicular subtypes as well as soft tissue sarcoma.' Study co-author James Larkin, consultant medical oncologist at The Royal Marsden and professor of precision cancer therapeutics at The Institute of Cancer Research, London, said: 'These significant results offer a compelling case for TIL therapy as a transformative option in melanoma care. 'The study demonstrates that for patients with few options left, a single infusion of lifileucel can provide a deep and lasting response and even complete remission in some cases. This marks a major advance in how we think about treating solid tumours.' Zoe Phillips, 46, from Dorset took part in the TIL therapy trial at The Royal Marsden. She was diagnosed with stage four melanoma in 2023 after previously being treated for skin cancer two years earlier. 'Six weeks after my first TIL therapy treatment, my scans showed that the tumours had completely disappeared,' Ms Phillips said. 'Before coming to The Royal Marsden I was told that I would probably die, so hearing that my treatment had been successful was amazing, I was over the moon. 'I come back to the hospital regularly for pembrolizumab immunotherapy treatment and currently still have no evidence of cancer.' Findings from the C-144-01 trial have been presented at the American Society of Clinical Oncology (Asco) annual meeting in Chicago.
